Impact of FDG-PET/CT on Management of Patients with Native Valve Infective Endocarditis
NCT ID: NCT04792281
Last Updated: 2024-11-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
97 participants
OBSERVATIONAL
2021-08-31
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Imaging Coronary Microvascular Dysfunction (CMD) Study
NCT05634031
PRetest prObability of Infectious ENDOCARDITIS for Appropriate Criteria Regarding Transesophageal ECHOcardiography in Tertiary Care Facilities (PRO ENDOCARDITIS ECHO-Study)
NCT03365193
Prospective Cohort Study of Patients With Infective Endocarditis at Pitié-Salpêtrière Hospital
NCT04992923
Individualized Diagnosis of Endocarditis and Its Therapy With a Focus on Infected Prosthetic materiAL
NCT02759978
Evaluation of a Metabolic Preparation by a Low-carbohydrate Diet as Atkins-diet to Help in Detecting Infective Endocarditis by 18F-FDG PET
NCT03465098
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with suspected native valve endocarditis
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Referred for a FDG-PET/CT study
* Classified as having Possible IE prior to FDG-PET/CT imaging;
* Patients must be able to tolerate the physical/logistical requirements of a PET/CT scan.
Exclusion Criteria
* Pregnant or breastfeeding female;
* Body mass index \> 45 kg/m2.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Montreal Heart Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Matthieu Pelletier-Galarneau, MD MSc
Assistant Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada
Montreal Heart Institute
Montreal, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
McGill University Health Center
Montreal, Quebec, Canada
University Institute of Cardiology and Respirology of Quebec
Québec, Quebec, Canada
Centre Hospitalier de l'Universite de Sherbrooke
Sherbrooke, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Daniel Juneau
Role: primary
Jean-Francois Sarrazin
Role: primary
Etienne Rousseau
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP-33-2020-2674
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.